S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
NASDAQ:MOR

MorphoSys (MOR) Stock Forecast, Price & News

$7.50
-0.01 (-0.13%)
(As of 09/22/2023 ET)
Compare
Today's Range
$7.38
$7.54
50-Day Range
$7.19
$8.60
52-Week Range
$3.17
$8.67
Volume
52,616 shs
Average Volume
131,829 shs
Market Capitalization
N/A
P/E Ratio
17.44
Dividend Yield
N/A
Price Target
$12.81

MorphoSys MarketRank™ Forecast

Analyst Rating
Hold
2.22 Rating Score
Upside/​Downside
70.8% Upside
$12.81 Price Target
Short Interest
Bearish
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.94) to ($2.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars


MOR stock logo

About MorphoSys (NASDAQ:MOR) Stock

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MOR Price History

MOR Stock News Headlines

MorphoSys (NASDAQ:MOR) Sees Large Volume Increase
MorphoSys (NASDAQ:MOR) Lifted to Neutral at The Goldman Sachs Group
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
JMP Securities Remains a Buy on Morphosys Ag (MOR)
DAX Gains Ahead Of US Inflation Data
MorphoSys Q2 Loss Narrows
What Wall Street expects from MorphoSys's earnings
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Company Calendar

Last Earnings
8/09/2023
Today
9/23/2023
Next Earnings (Estimated)
11/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MOR
Employees
544
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.81
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$9.25
Forecasted Upside/Downside
+70.8%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
9 Analysts

Profitability

Net Income
$-159,150,000.00
Pretax Margin
92.61%

Debt

Sales & Book Value

Annual Sales
$293.27 million
Book Value
$1.21 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.09
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jean-Paul  Kress M.D.Dr. Jean-Paul Kress M.D. (Age 58)
    Chairman of Management Board, MD & CEO
    Comp: $2.2M
  • Dr. Lucinda Crabtree Ph.D. (Age 44)
    CFO & Member of Management Board
  • Ms. Charlotte Lohmann (Age 53)
    Chief Legal Officer & Member of Management Board
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Ms. Lara Smith Weber
    Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn
    Sr. VP & Head of Investor Relations
  • Mr. Thomas Biegi
    VP & Head of Corp. Communications
  • Ms. Maria Castresana
    Sr. VP & Global Head of HR
  • Dr. Barbara Krebs-Pohl Ph.D.
    Chief Bus. Officer













MOR Stock - Frequently Asked Questions

Should I buy or sell MorphoSys stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View MOR analyst ratings
or view top-rated stocks.

What is MorphoSys' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price targets for MorphoSys' shares. Their MOR share price forecasts range from $9.25 to $17.00. On average, they anticipate the company's share price to reach $12.81 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price.
View analysts price targets for MOR
or view top-rated stocks among Wall Street analysts.

How have MOR shares performed in 2023?

MorphoSys' stock was trading at $3.58 at the beginning of the year. Since then, MOR shares have increased by 109.5% and is now trading at $7.50.
View the best growth stocks for 2023 here
.

When is MorphoSys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our MOR earnings forecast
.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) announced its earnings results on Wednesday, August, 9th. The company reported ($0.59) earnings per share for the quarter. The company had revenue of $57.91 million for the quarter. MorphoSys had a net margin of 27.67% and a trailing twelve-month return on equity of 154.85%.

What ETF holds MorphoSys' stock ?

Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio.

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did MorphoSys IPO?

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (0.00%), Point72 Asset Management L.P. (0.00%), Marshall Wace LLP (0.14%), Tekla Capital Management LLC (0.13%), Wells Fargo & Company MN (0.00%) and Artia Global Partners LP (0.00%).

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $7.50.

How many employees does MorphoSys have?

The company employs 544 workers across the globe.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The official website for the company is www.morphosys.com. The company can be reached via phone at (498) 989-9270, via email at investors@morphosys.com, or via fax at 49-89-8992-7222.

This page (NASDAQ:MOR) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -